Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\. Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy
2\. Provision of signed and dated written informed consent by the patient or legally acceptable representative
You may not be if
1\. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug
2\. Pregnancy and/or breast feeding
3\. Current participation in any interventional trial
Clareo Health | KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)
